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ABSTRACT 
A transferosome is the first generation of an elastic liposome prepared from phospholipids and edge activators. An edge activator is often a 
single-chain surfactant with a high radius of curvature that destabilizes the lipid bilayers of vesicles and increases the deformability of the 
bilayers, thereby making the vehicle ultra-deformable. Acyclovir is a synthetic purine nucleoside analog derived from guanine, is the most 
widely used antiviral agent. It is effective in the treatment of herpes simplex virus (HSV), mainly HSV-1 and HSV-2 and varicella-zoster virus. 
However, it has low skin permeability. Hence, the objective of this study was to prepare acyclovir using transferosomes to ov ercome the barrier 
function of the skin. The present study deals with the development of transferosomal gel containing acyclovir by handshaking method for 
painless acyclovir delivery for use in the treatment of skin disease through 33 Fractional factorial design in which amount of Phospholipid (A), 
Cholesterol (B) and Tween 80 (C) was selected as independent variables and vesicle size (X1) Polydispersity index (X2) and %entrapment 
efficiency (X3) as dependent variables. The prepared transferosomes were evaluated with respect to entrapment efficiency (EE %), particle 
size, and quantity of in vitro drug released to obtain an optimized formulation. The optimized formulation of acyclovir transferosomes was 
incorporated into a Carbapol 934 gel base which was evaluated for drug content, pH, spreadability, viscosity and in vitro permeation. The 
prepared acyclovir transferosomes had a high EE% ranging from 65 to 81%, with small particle sizes ranging from 181.9 to 401.8nm. The in 
vitro release study suggested that there was an inverse relationship between EE% and in vitro release. The formulation TF2 have better in-vitro 
drug release profile which contains carbopol 980 concentration 2 %w/w. The kinetic analysis of release profiles of TF2 was fo und to follow the 
Korsmeyer-Peppas model. All independent variables had a significant effect on the dependent variables (p-values < 0.05). Therefore, acyclovir 
in the form of transferosomes can penetrate the skin, overcoming the stratum corneum barrier.  
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INTRODUCTION 
Nanotechnology involves fabrication of nanoscale structures 
which are observed visibly under high resolution. These 
molecular assemblies are specially designed for attaining 
their target functions1. Based on their critical packing 
parameter and hydrophilic-lipophilic balance (HLB), these 
molecules are self-assembled to various morphologies 
including micelles, sheets and vesicles (liposomes, 
transferosomes, exsosomes, niosomes etc.)2. Furthermore, 
these vesicular formulations had been more exploited in the 
field of transdermal drug delivery3. They offer many 
advantages over conventional delivery systems like 
biocompatibility, non-toxicity, and ability to modify drugs' 
bioavailability4. In addition to the utilization of vesicular 
carriers for transdermal drug delivery, nano transfection 
approaches (TNT) have been recently introduced for topical 
and controllable delivery of reprogramming factors across 
the skin. These approaches allow delivery of controlling 
factors by applying an intense and highly focused electric 
field using arrayed nano-channel. Hence, TNT can deliver the 
cargo to the skin in a rapid and non-invasive manner5. In this 
manuscript, the strategy of using transferosome s as a 
vesicular nano-carrier has been selected and investigated for 
efficient transdermal delivering of drugs and bypassing their 
oral problems. Transferosomes are ultra-flexible vesicles 
with a bilayer structure. They can penetrate the skin easily 
and overcome the barrier function by squeezing through the 
intracellular lipid of the stratum corneum6. After application 
of Transferosomes on the skin, they move from the dry 
stratum corneum to a deep hydrated layer according to the 
osmotic gradient. The presence of surfactant in their 
structure helps in solubilizing the lipid in stratum corneum 
and permits high penetration of the vesicles7. Acyclovir [9-
(2-hydroxyethoxylmethyl) guanine], a synthetic purine 
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nucleoside analog derived from guanine, is the most widely 
used antiviral agent. It is effective in the treatment of herpes 
simplex virus (HSV), mainly HSV-1 and HSV-2 and varicella-
zoster virus. According to the biopharmaceutical 
classification system, acyclovir is categorized as a class - III 
drug i.e. having high solubility and less permeability. The 
pharmacokinetic parameters of acyclovir, following oral 
administration, are generally highly variable. It has an 
average plasma half-life of about 3 hours in adults with 
normal renal function. Its absorption in the GIT is slow, 
variable and incomplete. The bioavailability of acyclovir after 
oral administration ranges from 10-30%. Approximately 
80% of an oral dose is never absorbed and excreted through 
feces. Also, the frequency of administration of acyclovir is 
high, being 200mg five times a day up to 400mg five times a 
day depending upon the type of infection8. Pharmaceutical 
scientists often face the challenge of finding the appropriate 
combination of variables that will produce the product with 
optimum properties9. The optimization technique 
encompasses designing a set of an experiment that will 
reliably measure the response variables, fitting a 
mathematical model to the data, conducting an appropriate 
statistical test to assure that the best possible model is 
chosen and determining the optimum value of independent 
variables that produce the best response10. In the present 
investigation, we attempted to develop and optimize 
transferosomal gel containing acyclovir, for improved 
transdermal permeation using 33 factorial designs.  
EXPERIMENTAL 
Materials 
Acyclovir was obtained as a gift sample from Macleods 
Pharmaceuticals, Mumbai. Phospholipid was purchased from 
Himedia Laboratory, Mumbai. Ethanol, chloroform, 
cholesterol, tween 80 and carbopol-934 purchased from CDH 
chemical Pvt. Ltd. New Delhi. Dialysis membrane of Mol Wt 
cutoff 1200 was purchased from Himedia Laboratory, 
Mumbai. Demineralized and double distilled water was 
prepared freshly and used whenever required. All other 
reagents and chemicals used were of analytical grade. 
Preparation of transferosomes 
Transferosomes were prepared by hand-shaking method 
given by Vyas et al., 201111 with slight modification in which. 
The accurately weighed amounts (80-100 mg) of 
phospholipids, 10-30mg of cholesterol and Tween 80 (10-
30% w/v) were taken in a clean, dry, round-bottom flask and 
this lipid mixture was dissolved in a minimum quantity of 
methanol and chloroform mixture in a ratio of 2:1. The round 
bottom flask was rotated at 45ᵒ angle at room temperature. 
Final traces of solvents were removed under vacuum 
overnight. The prepared lipid film in the inner wall of the 
round bottom was hydrated with 10 ml of distilled water 
containing 10 mg of drug followed by rotating the flask. After 
complete hydration of film, the prepared formulation of 
transferosomes was subjected to sonication at 40ºC in 3 
cycles of 10 minutes with 5 sec rest between the cycles. The 
prepared formulation was stored at 4°C in a closed container 
until further use for analysis. 
Experimental design 
The response variables which will consider for systematic 
optimization were Vesicle Size, PDI, and % EE. For studied 
design, multiple linear regression analysis (MLRA) and 
ANOVA will be applied using Microsoft Excel® to fit first-
order multiple linear equations with added interaction terms 
to correlate the studied responses with the examined 
variables. The design expert software trial version will be 
used to contour and 3-D response curve.  
Factorial design and desirability function for optimizing 
transfersomes 
The coefficient estimate represents the expected change in 
response per unit change in factor value when all remaining 
factors are held constant. The intercept in an orthogonal 
design is the overall average response of all the runs. The 
coefficients are adjustments around that average based on 
the factor settings. When the factors are orthogonal the VIFs 
are 1; VIFs greater than 1 indicate multi-collinearity, the 
higher the VIF the more severe the correlation of factors. As 
a rough rule, VIFs less than 10 are tolerable. The number of 
experiments required for these studies is dependent on the 
number of independent variables selected the multiple linear 
regression equation given below. 
Table 1 List of variables employed in 33 factorial designs 
Factors Levels 
Low (-1) High (+1) 
Acyclovir 30 
Phospolipid 80.00 100 
Cholestrol 10.00 30.00 
Tween 80 10.00 30.00 
  
 
ANOVA for Quadratic model 
Response 1: Vesicle size 
Source Sum of Squares df Mean Square F-value p-value  
Model 62549.33 9 6949.93 5.81 0.0151 significant 
A-Phospolipid 2145.13 1 2145.13 1.79 0.2224  
B-Cholestrol 100.11 1 100.11 0.0837 0.7808  
C-Tween 80 9695.28 1 9695.28 8.10 0.0248  
AB 3358.20 1 3358.20 2.81 0.1378  
AC 1040.06 1 1040.06 0.8693 0.3822  
BC 11236.00 1 11236.00 9.39 0.0182  
A² 14093.48 1 14093.48 11.78 0.0110  
B² 17020.70 1 17020.70 14.23 0.0070  
C² 3594.98 1 3594.98 3.00 0.1266  
Residual 8375.24 7 1196.46    
Lack of Fit 4726.17 3 1575.39 1.73 0.2991 not significant 
Pure Error 3649.07 4 912.27    
Cor Total 70924.58 16     
Kumar et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):712-721  
ISSN: 2250-1177                                                                                  [714]                                                                                 CODEN (USA): JDDTAO 
The equation in terms of coded factors can be used to make 
predictions about the response for given levels of each 
factor. By default, the high levels of the factors are coded as 
+1 and the low levels are coded as -1. The coded equation is 
useful for identifying the relative impact of the factors by 
comparing the factor coefficients. The equation in terms of 
actual factors can be used to make predictions about the 
response for given levels of each factor. Here, the levels 
should be specified in the original units for each factor. This 
equation should not be used to determine the relative 
impact of each factor because the coefficients are scaled to 
accommodate the units of each factor and the intercept is 
not at the center of the design space. 
Final equation in terms of coded factors 
Vesicle Size = +216.64+16.38 A-3.54 B+34.81 C-28.98 
AB+16.13 AC+53.00 BC+57.85 BC+57.85 A²+63.58 B²-29.22 
C² 
Final equation in terms of actual factors 
Vesicle Size = +4811.11000-99.93150 Phospolipid-10.30825 
Cholestrol-9.94325 Tween 80-0.289750 Phospolipid * 
Cholestrol+0.161250 Phospolipid * Tween 80+0.530000 
Cholestrol * Tween 80+0.578550 Phospolipid²+0.635800 
Cholestrol²-0.292200 Tween 80² 
Final equation in terms of coded factors 
PDI=+0.2620+0.0050A-0.0050B+0.0125C-
0.0250AB+0.0100AC+0.0150BC+0.0265A2+0.0015B2-
0.0035C2 
Final equation in terms of actual factors 
PDI=+2.13050-0.044200 Phospolipid+0.018400 Cholestrol-
0.009350 Tween 80-0.000250 Phospolipid * 
Cholestrol+0.000100 Phospolipid * Tween 80+0.000150 
Cholestrol * Tween 80+0.000265 Phospolipid²+0.000015 
Cholestrol²-0.000035 Tween 80² 
Final equation in terms of coded factors 
% EE=+72.00+2.25 A+0.0000B-5.25C+1.0000 AB-1.00 AC-
1.0000BC 
Final Equation in Terms of Actual Factors 
%EE= +58.25000+0.225000Phospolipid-0.700000 
Cholestrol + 0.575000 Tween 80+ 0.010000 
Phospolipid*Cholestrol-0.010000Phospolipid*Tween80-
0.010000 Cholestrol* Tween 80 
 
Table 2 Array layout as 33 factorial screening designs 
Formulation Std Run 
Factor 1 Factor 2 Factor 3 
A:Phospolipid B:Cholestrol C:Tween 80 
F1 7 1 80 20 30 
F2 16 2 90 20 20 
F3 8 3 100 20 30 
F4 3 4 80 30 20 
F5 9 5 90 10 10 
F6 17 6 90 20 20 
F7 10 7 90 30 10 
F8 14 8 90 20 20 
F9 15 9 90 20 20 
F10 2 10 100 10 20 
F11 6 11 100 20 10 
F12 13 12 90 20 20 
F13 12 13 90 30 30 
F14 4 14 100 30 20 
F15 11 15 90 10 30 
F16 5 16 80 20 10 
F17 1 17 80 10 20 
 
Table 3 Optimized formula after post analysis 
S. No. Phospolipid Cholestrol Tween 80 
1. 98.528 28.302 10.015 
 
Evaluation of acyclovir loaded transferosomes 
Microscopic observation of prepared transferosomes 
An optical microscope (cippon, Japan) with a camera 
attachment (Minolta) was used to observe the shape of the 
prepared transferosomes formulation.  
Vesicle size and size distribution 
The vesicles size and size distribution were determined by 
Dynamic Light Scattering method (DLS) (Malvern 
Zetamaster, ZEM 5002, Malvern, UK). 
Zeta potential 
The zeta potential was calculated according to Helmholtz–
Smoluchowsky from their electrophoretic mobility. For 
measurement of zeta potential, a zeta sizer was used with a 
field strength of 20 V/cm on a large bore measures cell. 
Samples were diluted with 0.9% NaCl adjusted to a 
conductivity of 50 lS/cm. 
Entrapment efficiency 
Entrapment efficiency was determined by measuring the 
concentration of unentrapped free drug in an aqueous 
medium. About 1 ml of the drug-loaded ethosomes 
dispersion was placed in the Ependorf tubes and centrifuged 
at 17000 rpm for 30 min. The ethosomes along with 
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encapsulated drug were separated at the bottom of the 
tubes. Plain ethosomes without drug was used as a blank 
sample and centrifuged in the same manner. In order to 
measure the free drug concentration, the UV absorbance of 
the supernatant was determined at 242 nm. 
Preparation of transferosomes gels 
Carbopol gel was prepared by soaking carbopol 934 (1-
3%w/v) in 20 ml of water for 2 hours. Triethanalamine was 
added to above solution to neutralizing the solution with 
continuous stirring. The carbopol dispersion was stirred at 
200 rpm for 24 hr min to complete hydration and obtaining 
a homogeneous gel. The previously prepared drug loaded 
transferomes (equivalent to 20 mg of acyclovir) formulation 
was added to the above dispersion and stirred again for 20 
min at 100 rpm. The pH of the gel was adjusted to 6.5-7.0 by 
adding triethanolamine.  The composition of acyclovir gel 
formulation was given in table 4. 
Table 4 Formulation of transfersomes gel 
S. 
No. 
Formulation Code Carbopol 934 
(gm) 
Water 
1. TF1 1 100 
2. TF2 2 100 
3. TF3 3 100 
 
Evaluation of gel  
Physical characteristic  
The Physical characteristic was checked for gel formulations 
(homogeneity and texture). 
Determination of pH  
The pH of the gels was determined by digital pH meter. One 
gram of gel was dissolved in 25 ml of distilled water and the 
electrode was then dipped into gel formulation for 30 min 
until constant reading obtained. And constant reading was 
noted. The measurements of pH of each formulation were 
replicated two times. 
Washability 
Formulations were applied on the skin and then ease and 
extent of washing with water were checked manually. 
Extrudability study  
The gel formulations were filled into collapsible aluminum 
tubes. The tubes were pressed to extrude the material and 
the extrudability of the formulation was checked.  
Spreadability  
An important criterion for gels is that it must possess good 
spreadability. Spreadability is a term expressed to denote 
the extent of the area to which the gel readily spreads on 
application to the skin. The therapeutic efficacy of a 
formulation also depends on its spreading value. A special 
apparatus has been designed to study the spreadability of 
the formulations. Spreadability is expressed in terms of time 
in seconds taken by two slides to slip off from formulation, 
placed between, under the application of a certain load. 
Lesser the time is taken for the separation of two slides, 
better the spreadability. It is determined by the formula 
given below. 
Where, S=Spreadability (gcm/sec), m = weight tied to the 
upper slide (20 grams),  
l= length of glass slide (6cms), t = time taken is seconds. 
Viscosity  
The measurement of viscosity of the prepared gel was done 
using Brookfield Viscometer. The viscosity was measured 
using spindle no. 6 at 10 rpm and 25ºC. The sufficient 
quantity of gel was filled in an appropriate wide mouth 
container which can allow dipping the spindle of the 
Viscometer. Samples of the gels were allowed to settle over 
30 min at the constant temperature (25 ±1ºC) before the 
measurements.  
In-vitro drug release studies using the prehydrated 
cellophane membrane  
The cellophane membrane approximately 25 cm x 2cm was 
taken and washed in the running water. It was then soaked 
in distilled water for 24 hours before used for diffusion 
studies to remove glycerin present on it and was mounted 
on the diffusion cell for further studies. The drug release 
studies were carried out using a modified Franz diffusion 
cell. The cellophane membrane was mounted on the Franz 
diffusion cell. The formulation was applied through a donor 
compartment on the dialysis membrane. Reservoir 
compartment was filled with 25 ml phosphate buffer of pH 
7.4 The study was carried out at 37 ± 1°C and a speed of 100 
rpm for 8 h. Samples were withdrawn from reservoir 
compartment at 1 h interval and absorbance was measured 
spectrophotometrically at 242 nm. Each time the reservoir 
compartment was replenished with the same quantity of 7.4 
pH phosphate buffer12,13. 
Release kinetics 
To elucidate mode and mechanism of drug release, the in-
vitro data was transformed and interpreted at a graphical 
interface constructed using various kinetic models. The 
zero-order release Eq. (1) describes the drug dissolution of 
several types of modified release pharmaceutical dosage 
forms, as in the case of transdermal systems, matrix tablets 
with low soluble drugs, coated forms, osmotic systems, etc., 
where the drug release is independent of concentration.  
Qt = Qo + Kot (1) 
Where Qt is the amount of drug released in time t, Qo is the 
initial amount of the drug in the solution and Ko is the zero-
order release constant  
The first order Eq. (2) describes the release from the system 
where the release is concentration-dependent e.g. 
pharmaceutical dosage forms containing water-soluble 
drugs in porous matrices.  
log Qt = log Qo + K1 t /2.303 (2) 
Where Qt is the amount of drug released in time t, Q is the 
initial amount of drug in the solution and K1 is the first-
order release constant.  
Higuchi described the release of drug from insoluble matrix 
as a square root of time as given in Eq. (3)  
Qt = KH √t (3) 
Where Qt is the amount of drug released in time t, KH is 
Higuchi's dissolution constant14.  
The following plots were made: cumulative % drug release 
vs. time (zero-order kinetic models); log cumulative of % 
drug remaining vs. time (first-order kinetic model); 
cumulative % drug release vs. square root of time (Higuchi 
model). 
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Stability studies 
Stability study was carried out for drug-loaded 
transferosomes gel (TF2) at two different temperatures i.e. 
refrigeration temperature (5ºC±3 °C) and at room 
temperature (25±2°C) and 60%±5% RH with for 90 days. 
The formulation subjected to stability study was stored in 
borosilicate container to avoid any interaction between the 
formulation and glass of container. The formulations were 
analyzed for vesicle size and % drug content. 
RESULTS AND DISCUSSIONS 
The response surface (33) factorial design was applied to 
optimize the number of formulation and process variables 
for the preparation of drug bearing transferosomes. Various 
batches of transferosomes were prepared as obtained by 
Design Expert Software version 11.1.0 and than 
characterized for average particles size, PDI and percent 
drug entrapment efficiency. It was observed that as on 
increasing the concentration of lipid from 80mg to 100mg 
the size of transferosomes was increase. Vesicle size and PDI 
of the transferosomes were measured by photon correlation 
spectroscopy using a Malvern Zetasizer and entrapment 
efficiency was determined by measuring the concentration 
of unentrapped free drug in aqueous medium by UV 
spectrophotometer the results shown in Table 5 & Figure 1-
8.
  
Table 5 Evaluation of formulations 33 factorial design 
S. No. Formulation Vesicle Size nm PDI % EE 
1 F1 276.4 0.28 65 
2 F2 238.2 0.26 72 
3 F3 327.6 0.32 68 
4 F4 332.3 0.31 69 
5 F5 286.7 0.27 76 
6 F6 258.5 0.27 71 
7 F7 189.5 0.23 78 
8 F8 202.7 0.27 73 
9 F9 189.3 0.25 72 
10 F10 401.8 0.32 73 
11 F11 181.9 0.27 81 
12 F12 194.5 0.26 72 
13 F13 321.3 0.28 66 
14 F14 320.9 0.26 75 
15 F15 206.5 0.26 68 
16 F16 195.2 0.27 74 
17 F17 297.3 0.27 71 
 
 
The normal probability plot indicates whether the residuals 
follow a normal distribution or not. In figure 3(a) all the 
points are showing near the strait line which indicates that a 
transformation of the response may provide a better 
analysis. The plot of the residuals versus the ascending 
predicted response values (not showing in the manuscript) 
tests the assumption of constant variance. The plot was 
shown a random scatter (constant range of residuals across 
the graph) which indicates the no need for a transformation. 
2D contour plot and 3D response surface plots for vesicle 
size clearly shows that as increasing the concentration of 
phospolipid and cholesterol the average vesicles size was 
increase. High concentration of lipid may form high dense 
layers which may result in the formation of multilameller 
vesicles and the size of the multilameller transferosomes 
was increase. 
The main effect of A, B, and D represents the average result 
of changing variable at a time from its low level to high level. 
The interaction terms (AB, AC, BC, A2, B2, and C2) show how 
the percent drug entrapment changes when 2 variables are 
simultaneously changed. Among the 3 independent variable 
the lowest coefficient value is for C (-0.32 & P<0.05) 
indicating that this variable is insignificant in the prediction 
of percent drug entrapment. It is also observed that the drug 
entrapment does not significantly change (P<0.05) because 
as on changing stirring speed from 3000 rpm to 5000 rpm 
there is very little decrease in the percent drug entrapment 
which shows very less amount of drug loss due to size 
reduction of the transferosomes. 
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Figure 1 (a) Normal plot of residuals and (b) Contour plots for vesicle size 
 
Figure 2 3D Response surface plots for Vesicle Size 
 
In the case of PDI of transfersomes, the normal plot showing 
that all the points near the strait line of the plot which 
revealed that a transformation of the response may provide a 
better analysis. Contour plot and 3D graph were shown that 
the PDI was increase with increasing the concentration of 
lipid. Higher concentration of lipid may leads to formation of 
vesicles of different size.  
 
 
Figure 3 contour plots for PDI 
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Figure 4 3D Response surface plot for PDI 
 
 
Figure 5 Contour plot for % EE 
 
Figure 6 Response surface plot for % EE 
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Figure 7 Contour plots for all parameters 
 
Figure 8 Overlain plot for all parameters 
Vesicle size, PDI, % EE and desirability of optimized 
formulation after post analysis was given in table 6. The 
vesicle size and % EE of optimized formulation was found to 
be 171.49 nm and 87.54% respectively. 
 
Table 6 Optimized formulation after post analysis 
S. No. Vesicle Size (nm) PDI % EE Desirability 
1. 171.494 0.228 87.549 1.000 
 
Results of the evaluation of transferosomal gel formulation 
(TF1-TF3) of optimized formulation were incorporated into 
three different carbapol gel concentration 1, 2 and 3%w/w 
respectively. Formulation TF2 was found to be good Table 7. 
Results of In-vitro drug release from optimized formulation 
(TF2) are given in Table 8 was found 62.5 after 72 hrs. The in 
vitro drug release data of the formulation was subjected to 
the goodness of fit test by linear regression analysis 
according to zero order, first-order kinetic equation and 
Korsmeyer's -Pappas models to determine the mechanism of 
drug release. When the regression coefficient values of were 
compared, it was observed that ‘r' values of the formulation 
were maximum i.e 0.990 hence indicating drug release from 
formulations was found to follow Korsmeyer-Peppas model 
of drug release kinetics Table 9 & Figure 9-12. 
 
Table 7 Optimization of transfersomes gel formulations 
Code Drug content 
(%) 
pH Spreadability 
(gm.cm/sec.) 
Viscosity 
(cps) 
TF1 97.30±0.23 6.78±0.03 6.84±0.12 4850±12 
TF2 98.74±0.45 6.99±0.02 5.16±0.21 4278±15 
TF3 97.18±0.36 6.85±0.04 4.65±0.25 5325±10 
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Table 8 In-vitro drug release data for transfersome gel TF2 
Time 
(h) 
Square Root 
of Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
0.12 0.346 -0.921 5.84 0.766 94.16 1.974 
0.5 0.707 -0.301 11.05 1.043 88.95 1.949 
1 1.000 0.000 15.39 1.187 84.61 1.927 
2 1.414 0.301 18.36 1.264 81.64 1.912 
4 2.000 0.602 21.7 1.336 78.3 1.894 
6 2.449 0.778 24.11 1.382 75.89 1.880 
8 2.828 0.903 25.63 1.409 74.37 1.871 
12 3.464 1.079 31.35 1.496 68.65 1.837 
24 4.899 1.380 40.16 1.604 59.84 1.777 
48 6.928 1.681 50.06 1.699 49.94 1.698 
72 8.485 1.857 62.5 1.796 37.5 1.574 
 
Table 9 Release Kinetics Regression values of formulation TF1-TF3 
Formulation 
code 
Zero order First order Higuchi Korsmeyer-Peppas 
TF1 Y=0.499x+19.33 
0.774 
Y=-0.003x+1.907 
0.839 
Y= 4.849x+12.18 
0.928 
Y= 0.279x+1.197 
0.989 
TF2 Y=0.694x+16.61 
0.900 
Y=-0.005x+1.925 
0.960 
Y= 6.464x+7.544 
0.989 
Y= 0.346x+1.130 
0.990 
TF3 Y=0.606x+14.81 
0.844 
Y=-0.004x+1.933 
0.905 
Y= 5.728x+6.629 
0.955 
Y= 5.728x+6.629 
0.964 
 
 
 
Figure 9 Graph of Zero order Release Kinetics of 
transfersome gel TF2 
 
 
Figure 10 Graph of first order Release Kinetics of 
transfersome gel TF2 
 
 
Figure 11 Graph of Higuchi release Kinetics of 
transfersome gel TF2 
 
 
Figure 12Graph of Korsmeyer-Peppas release Kinetics 
of transfersome gel TF2 
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Stability study was carried out for drug loaded 
transferosomes gel (TF2) at two different temperatures i.e. 
refrigeration temperature (4.0±0.5°C) and at room 
temperature (28± 0.5°C) for 90 days. The formulations 
were analyzed for any vesicle size and drug content (figure 
13 & 14). 
 
Figure 13 Effect of storage temperature on the vesicle 
size 
 
 
Figure 14 Effect of storage temperature on drug 
content 
CONCLUSION 
From this study, it was concluded that the factorial design 
(33) coulcould obtain an optimized formula of acyclovir, 
with high EE%, small particle size, and high transdermal 
flux. Also, the preparation of acyclovir as transfersomal gel 
can overcome the barrier properties of the skin and 
increase the antiviral activity and avoiding its oral 
problems and consequently improving patient compliance. 
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